Prostate cancer gene therapy - Corautus Genetics

Drug Profile

Prostate cancer gene therapy - Corautus Genetics

Alternative Names: IL-3 Dual-AD

Latest Information Update: 29 May 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Corautus Genetics
  • Developer Corautus Genetics; Immune Response Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Immunomodulators; Interleukin 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 29 May 2003 Discontinued - Preclinical for Prostate cancer in USA (Intratumoural)
  • 19 Feb 2003 GenStar Therapeutics Corporation has merged with Vascular Genetics to form Corautus Genetics
  • 17 Feb 2003 Suspended - Preclinical for Prostate cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top